Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR ) 37.77 -0.36 (-0.95%) Streaming Delayed Price Updated: 1:50 PM EDT, Sep 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Structure Therapeutics Inc. - American Depositary Shares < Previous 1 2 3 4 Next > The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race August 29, 2024 The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. Via Investor's Business Daily Structure Therapeutics Appoints Angus C. Russell to Board of Directors August 27, 2024 Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Participation in Upcoming Investor Conferences August 26, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Peering Into Structure Therapeutics's Recent Short Interest July 15, 2024 Via Benzinga 3 Promising Biotech Stocks for the Long-Term: August 2024 August 13, 2024 Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few. Via InvestorPlace GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024 August 09, 2024 GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights August 08, 2024 From Structure Therapeutics Inc. Via GlobeNewswire 3 Biotech Stocks That Could Make Your Summer Unforgettable July 30, 2024 If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. Via InvestorPlace Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon. July 22, 2024 Eli Lilly is still a smart pick, but these two stocks could grow more in the near term. Via The Motley Fool Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review July 19, 2024 The Nasdaq tumbled amid chip woes. Via Investor's Business Daily Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 17, 2024 Via Benzinga Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? July 17, 2024 Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... Via Benzinga ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session July 17, 2024 Via Benzinga The 3 Most Undervalued Biotech Stocks to Buy in July 2024 July 12, 2024 There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. Via InvestorPlace Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug July 09, 2024 Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been Via MarketBeat Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? July 03, 2024 Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases Via MarketBeat Exposures Product Safety Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes July 02, 2024 Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy Via MarketBeat The 3 Smartest Biotech Stocks to Buy With $5K Right Now June 28, 2024 With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. Via InvestorPlace Could Structure Therapeutics Become the Next Novo Nordisk? June 17, 2024 Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds. Via The Motley Fool Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar June 14, 2024 The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. Via Investor's Business Daily Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? June 11, 2024 Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. Via The Motley Fool Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet June 10, 2024 The company is focusing on obesity treatment after its glaucoma drug failed. Via Investor's Business Daily Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy? June 09, 2024 Structure Therapeutics has a long way to go before beating Wegovy. Via The Motley Fool Top Names Performance Update - Saturday, June 8 June 08, 2024 I usually show the performance of the top names cohort from six months earlier, but we didn’t have the full, six-month performance of our Dec. 7 top names cohort yet, so here is a stand-alone... Via Talk Markets Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million June 08, 2024 Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... Via Talk Markets Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares June 07, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering June 05, 2024 From Structure Therapeutics Inc. Via GlobeNewswire The 3 Most Undervalued Biotech Stocks to Buy in June 2024 June 04, 2024 https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate Via InvestorPlace Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants June 03, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says June 03, 2024 Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
